Zanamivir
From Proteopedia
(Difference between revisions)
| Line 22: | Line 22: | ||
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ||
! 10 | ! 10 | ||
| - | ! | + | ! 42 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
| Line 42: | Line 42: | ||
! Metabolism | ! Metabolism | ||
! None | ! None | ||
| - | ! | + | ! Hepatic |
|} | |} | ||
<references/> | <references/> | ||
Revision as of 15:07, 8 December 2010
Pharmacokinetics
| Neuraminidase Inhibitor Pharmacokinetics[1][2] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Ritonavir | Oseltamivir | |||||||||
| Tmax (hr) | 1.25 | 1.5 | |||||||||
| Cmax (ng/ml) | 31.6 | 57 | |||||||||
| Bioavailability (%) | 2 | 75 | |||||||||
| Protein Binding (%) | 10 | 42 | |||||||||
| T1/2 (hr) | 3 | 3.2 | |||||||||
| AUC (ng/ml/hr) | 185 | 204 | |||||||||
| Clearance (L/h) | 54.1 | Oseltamivir | |||||||||
| Dosage (mg) | 10 | 300 | |||||||||
| Metabolism | None | Hepatic | |||||||||
- ↑ A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009
- ↑ Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003 Sep;59(5-6):411-5. Epub 2003 Aug 9. PMID:12910331 doi:http://dx.doi.org/10.1007/s00228-003-0639-6
